More than a decade ago, the Singaporean government decided to invest heavily in the infrastructure needed to smooth the transit of pharmaceuticals – including clinical trial supplies, and subsequently target the life sciences industry. Sue Lee of World Courier explores how their decision to do so is now reaping rewards.